Zobrazeno 1 - 10
of 136
pro vyhledávání: ''
Autor:
Priya Kumthekar, Anita Fung, Nan Lin, Anna Cheng, Nuhad K. Ibrahim, Solmaz Sahebjam, Mark D. Pegram, Alan Nicholas, Whitney P. Kirschbrown
Publikováno v:
Journal of Clinical Oncology. 39:2667-2675
PURPOSE Effective therapies are needed for the treatment of patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) with brain metastases. A trastuzumab radioisotope has been shown to localize in brain me
Autor:
Roberto Hegg, Hiroji Iwata, G. Kurteva, Michael F. Press, Miguel Izquierdo, Olga Burdaeva, Sergei Tjulandin, Sergio Daniel Simon, Seock-Ah Im, In Hae Park, Sarah Kenny, William J. Gradishar, L. S. Williams, Stephen R. D. Johnston, Severine Sarp
Publikováno v:
J Clin Oncol
PURPOSE Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)–positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances cli
Autor:
Junji Tsurutani, Caleb Lee, Ian E. Krop, Shunji Takahashi, Rashmi Krishna Murthy, Alvaro Moreno-Aspitia, Javad Shahidi, Masahiro Sugihara, Haeseong Park, Yasuaki Sagara, Kenji Tamura, Lin Zhang, Charles H. Redfern, Yoshihiko Fujisaki, Hiroji Iwata, Shanu Modi, Toshihiko Doi
Publikováno v:
Journal of Clinical Oncology. 38:1887-1896
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evalua
Autor:
Rashmi Krishna Murthy, Amelia Zelnak, Giuseppe Curigliano, Carey K. Anders, Elisavet Paplomata, Mafalda Oliveira, Eric P. Winer, Virginia F. Borges, Karen A. Gelmon, Alison Conlin, Xuebei An, Michael DiGiovanna, Sibylle Loibl, Alicia Okines, Sara A. Hurvitz, Ruth O'Regan, Philippe L. Bedard, Andrew M Wardley, Lisa A. Carey, Thomas Bachelot, Jo Al Mayor, David Cameron, A. Jo Chien, Nan Lin, Sherene Loi, Vandana G. Abramson, Suzanne McGoldrick, Erika Hamilton, Volkmar Mueller
Publikováno v:
Journal of Clinical Oncology
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23
Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775
BASE-Bielefeld Academic Search Engine
Scientia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 23
Lin, N U, Borges, V, Anders, C, Murthy, R K, Paplomata, E, Hamilton, E, Hurvitz, S, Loi, S, Okines, A, Abramson, V, Bedard, P L, Oliveira, M, Mueller, V, Zelnak, A, Digiovanna, M P, Bachelot, T, Chien, A J, O’regan, R, Wardley, A, Conlin, A, Cameron, D, Carey, L, Curigliano, G, Gelmon, K, Loibl, S, Mayor, J, Mcgoldrick, S, An, X & Winer, E P 2020, ' Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial ', Journal of Clinical Oncology, pp. JCO.20.00775 . https://doi.org/10.1200/JCO.20.00775, https://doi.org/10.1200/JCO.20.00775
BASE-Bielefeld Academic Search Engine
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We desc
Autor:
Quchang Ouyang, Shusen Wang, Shiying Yu, Zhongsheng Tong, Zefei Jiang, Wei Li, Jianjun Zou, Xichun Hu, Y Liu, Fei Ma, Xiaoyu Zhu, Huiping Li, Jifeng Feng, Binghe Xu
Publikováno v:
Journal of Clinical Oncology. 37:2610-2619
PURPOSE Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine,
Autor:
Rebecca J. Nagy, Jeff Sperinde, Ashok Srinivasan, Jan H. Beumer, A Montero, Rachel C. Jankowitz, Fanny Piette, Samuel A. Jacobs, Carmen J. Allegra, Weidong Huang, Richard B. Lanman, Peter C. Lucas, Laura M Adamson, Brian F. Kiesel, Mohamad Adham Salkeni, Ying Wang, Katherine L. Pogue-Geile, Jame Abraham
Publikováno v:
Journal of Clinical Oncology
PURPOSE Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well elucidated.
Autor:
Miguel Martin, Vicente Valero, Sara A. Hurvitz, Chiun-Sheng Huang, Daniil Stroyakovskiy, Mario Campone, Vanesa Lopez-Valverde, Peter Trask, Gonzalo Spera, Jean Francois Boileau, Chunyan Song, Peter A. Fasching, W. Fraser Symmans, Kyung Hae Jung, Joseph A. Sparano, Hans Wildiers, Thomas Boulet, Alastair M. Thompson, Karen Afenjar, Nadia Harbeck, Dennis J. Slamon
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 25
Journal of Clinical Oncology
Journal of Clinical Oncology
PURPOSE The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2–positive stage II to III breast cance
Autor:
Antonio C. Wolff, Ashley Carpenter, Richard L. Wahl, Ian E. Krop, Roisin M. Connolly, Melissa Camp, Anna Maria Storniolo, Lilja Solnes, Vandana G. Abramson, Vered Stearns, Eric P. Winer, Jennifer M. Specht, Robert S. Miller, Ashley Cimino-Mathews, Jeffrey P. Leal, Vicente Valero, Chiung Yu Huang, Mothaffar F. Rimawi, Lisa A. Carey, Minetta C. Liu, Katy Gaffney, Christos Vaklavas, Ben Ho Park
Publikováno v:
J Clin Oncol
PURPOSE Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standa
Autor:
Hideaki Takahashi, Yuichiro Tada, Shuhei Yamada, Hiroya Ojiri, Hideaki Hirai, Takashi Matsuki, Kaori Tani, Kohei Akazawa, Robert Yoshiyuki Osamura, Shin Etsu Kamata, Daisuke Kawakita, Toshitaka Nagao, Chihiro Fushimi, Tatsuo Masubuchi, Kouki Miura, Takashi Saotome
Publikováno v:
Journal of Clinical Oncology. 37:125-134
Purpose Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease’s rarity. We assessed the efficacy and toxicity of trastuzumab plus docetaxel in patients wit
Autor:
Eric P. Winer, Jennie R. Crews, Nan Lin, Sarat Chandarlapaty, Francisco J. Esteva, Ian E. Krop, Debra A. Patt, Nancy E. Davidson, Jennifer Levinson, Sharon H. Giordano, Naren Ramakrishna, Jeffrey J. Kirshner, Sarah Temin, Shanu Modi, Jane Perlmutter
Publikováno v:
Journal of Clinical Oncology. 36:2736-2740
Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer to 2018. Methods An Expert Panel